Risk Mitigation for Oncology Clinical Trials

Since early 2020, the oncology clinical trials industry has made rapid changes in order to ensure mission-critical operations continue to protect participant rights, privacy, safety and data integrity. Particularly at clinical sites, research teams have had to restructure their staff and operations according to institutional directives to prevent the spread of COVID-19 while continuing to offer trial options to patients, with some regions more deeply affected than others.

In this webinar, Julie Martin, CEO & co-Owner of Scimega Research, will present on key areas of risk for US sponsors in critical oncology clinical trial operations in Canada and other geographic areas, and share mitigating tactics and strategies to build resiliency in 2021-2022 and maximize clinical development progress.

Register for this webinar to explore ways to ensure continuation of critical clinical trial operations through the pandemic and learn strategies for prevention of further delays, and how to achieve recovery and resiliency in 2021-2022. Specific topics to be discussed include:

• Key risk areas of greatest concern in oncology clinical trials
• Strategies used to mitigate threats in 2020 for small and mid-size US oncology biotechs: what worked and what didn’t
• Cutting-edge small & mid-size oncology biotech trials: where to run them and which aspects may be different moving forward
• What decision factors are expected to most influence your choice of region(s) in 2021-2022, including speed of start-up, participant diversity and regional participation rates

Bonus Offer: Register now and receive immediate access to the white paper Expert Guidance to Key Advantages of Canadian Regulatory Landscape.

Speaker

Julie Martin, CEO & co-Owner, Scimega

Julie joined Scimega 8 years ago. Having worked for 2 other CROs before, her passion for Scimega’s business and team stems from knowing its expert oncology clinical development services add distinct value to industry stakeholders at a time when it’s needed most.

As CEO, Julie’s vision is to secure the company’s long-term success by leveraging her in-depth industry expertise & business acumen. She equates that success with setting a clear vision for the organization’s continued sense of purpose. Julie is responsible for developing successful business strategies & leveraging industry opportunities, all of which support the common vision she shares with her team.

Her leadership & collaboration with the managing Board of Directors ensure the business excellence upon which Scimega has built its reputation. Julie plays a vital role in promoting Scimega’s expertise and showcasing Canada’s attributes as a formidable partner in global oncology drug development.

Message Presenter